文献速递腹部介入CTMRUS

治疗前影像诊断为肝细胞癌的小病灶(≤3 cm):肝切除与射频消融治疗结局比较

Small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging: comparison of therapeutic outcomes between hepatic resection and radiofrequency ablation.
PubMed 文献 · Br J Radiol · 2019-11-04

本回顾性研究纳入2008年1月至2009年12月治疗前影像诊断为肝细胞癌的单发≤3 cm病灶患者,肝切除组145例、射频消融组178例。肝切除组5年无复发生存率59.3%、总生存率85.4%,射频消融组分别为32.2%和76.8%;多因素分析显示治疗方式并非无复发生存或总生存的独立预后因素。肝切除组影像诊断假阳性率为4.8%,射频消融组1年和3年累积局部肿瘤进展率分别为8.3%和20.2%。

要点

  • 治疗前影像诊断肝细胞癌的小病灶(≤3 cm)影像标准假阳性率4.8%,阳性预测值高。
  • 肝切除组5年无复发生存率59.3% vs 射频消融组32.2%,但多因素分析未显示治疗方式是独立预后因素。
  • 射频消融组1年和3年累积局部肿瘤进展率分别为8.3%和20.2%。

核心结论

  • 治疗前影像诊断肝细胞癌的影像标准具有高阳性预测值,假阳性率4.8%。
  • 多因素分析显示,治疗前影像诊断为肝细胞癌的小病灶(≤3 cm),肝切除与射频消融的无复发生存率和总生存率无显著差异。
  • 治疗方式(肝切除 vs 射频消融)不是无复发生存或总生存的独立预后因素。

研究设计与样本

  • 回顾性研究,经本机构审查委员会批准并豁免知情同意。
  • 纳入2008年1月至2009年12月治疗前影像诊断为肝细胞癌的单发≤3 cm病灶患者,肝切除组145例、射频消融组178例。
  • 评估无复发生存率和总生存率;肝切除组计算影像诊断假阳性率,射频消融组计算局部肿瘤进展率。

诊断标准与关键数值

  • 肝切除组基于影像标准诊断肝细胞癌的假阳性率为4.8%。
  • 射频消融组1年和3年累积局部肿瘤进展率分别为8.3%和20.2%。
  • 肝切除组5年无复发生存率59.3%,射频消融组32.2%。
  • 肝切除组5年总生存率85.4%,射频消融组76.8%。

临床应用与阅片要点

  • 治疗前影像诊断为肝细胞癌的小病灶(≤3 cm),影像标准假阳性率4.8%,提示阳性预测值高。
  • 多因素分析显示肝切除与射频消融的无复发生存率和总生存率无显著差异,治疗方式不是独立预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare therapeutic outcomes between hepatic resection (HR) and radiofrequency ablation (RFA) for small hepatic masses diagnosed as hepatocellular carcinoma (HCC) on pre-treatment imaging study.

METHODS: Our institutional review board approved this retrospective study, and informed consent was waived. Patients with a single (≤3 cm) mass diagnosed as HCC on pre-treatment imaging study between January 2008 and December 2009 who underwent HR (n = 145) or RFA (n = 178) were included. Recurrence-free survival (RFS) and overall survival (OS) were assessed. In the HR group, the false-positive rate for imaging diagnosis was calculated. For the RFA group, the local tumor progression rate was calculated.

RESULTS: RFS rates at 5 years were 59.3% for the HR group and 32.2% for the RFA group. OS rates at 5 years were 85.4% for the HR group and 76.8% for the RFA group. In the RFA group, cumulative local tumor progression rates were 8.3 and 20.2% at 1 and 3 years. Treatment modality was not an independent prognostic factor for either RFS or OS on multivariate analysis. The false-positive rate for HCC diagnosis based on imaging criteria was 4.8% in the HR group.

CONCLUSION: The imaging criteria for diagnosis of HCC have a high positive predictive value. Multivariate analysis showed that RFS and OS rates were not significantly different between HR and RFA for small hepatic masses diagnosed as HCC on pre-treatment imaging.

ADVANCES IN KNOWLEDGE: Treatment modality (hepatic resection vs RFA) was not an independent prognostic factor for both RFS and OS for small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Cha DI, Song KD, Kang TW, et al. Small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging: comparison of therapeutic outcomes between hepatic resection and radiofrequency ablation. Br J Radiol. 2019. PMID: 31670571. doi:10.1259/bjr.20190719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。